A Phase 3 interventional study of Pegvaliase in Phenylketonuria (PKU), sponsored by BioMarin Pharmaceutical. Completed at 17 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-02-17.
Sponsored by BioMarin Pharmaceutical · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing pegvaliase in Phenylketonurias — 1 open to participants now, 2 under way, 1 of them phase 3. pegvaliase · Phenylketonurias.
Among the 10 studies testing pegvaliase in Phenylketonurias, this one is the 6th largest by enrollment, is the only one that started in 2018, is one of 4 in phase 3, and was the 8th registered.
191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.
Browse Phenylketonurias studies →1 of the 10 studies testing pegvaliase in Phenylketonurias is open now, in 1 country. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in United States
Ages 18–65
By country, each count listing its studies:
pegvaliase: first FDA approval 2018 (PALYNZIQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2018.
This study's enrollment of 37 is above the median of 27 across 122 interventional studies indexed under Phenylketonurias.
Median enrollment 39 across the 10 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
BioMarin Pharmaceutical is the lead sponsor of 112 studies on the registry; 13 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 12 (63%) have results posted.
35 studies in Phenylketonurias by BioMarin Pharmaceutical: 3 open now, 5 under way, 1 of them phase 3. Of 29 finished, 17 (59%) have results posted.
Among the 35 studies in Phenylketonurias by BioMarin Pharmaceutical, this one is the 18th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2018, is one of 11 in phase 3, and was the 27th registered.
BioMarin Pharmaceutical’s Phenylketonurias studies by the year they started, since 2004.
1 of the studies testing pegvaliase in Phenylketonurias that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477691BioMarin PharmaceuticalImmune Modulation During Palynziq® Treatment in Adults (IMPALA) | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing pegvaliase in Phenylketonurias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among BioMarin Pharmaceutical’s 35 in Phenylketonurias:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3 open-label extension study enrolling adult patients with PKU who were previously treated with pegvaliase in Studies PAL-003 (NCT00924703) or 165-302 (NCT02468570). The study is designed to evaluate the long-term safety and efficacy of pegvaliase administered at doses > 40 mg/day to 60 mg/day.
Pegvaliase dosing will continue without interruption from Parent Study 165-302 (NCT02468570) or Parent Study PAL-003 (NCT00924703). Beginning on Day 1, subjects will receive the same dose and regimen of pegvaliase they were receiving in either 165-302 or PAL-003. A subject who reduces to a dose of 40 mg/day or lower for 32 consecutive weeks will be discontinued from study drug and withdrawn from the study as they will have the option to transition to commercial drug. Dose reductions may be performed if warranted due to AEs or hypophenylalaninemia. Dose increases to up to 60 mg/day may be performed per investigator discretion in consultation with the sponsor's medical monitor. Dosing will continue for approximately 121 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Beginning on Day 1, subjects will receive the same dose and regimen of pegvaliase they were receiving in 165-302 or PAL-003 (pegvaliase dosing should continue without interruption from the previous study). Subsequent revisions to dosing regimens are allowed following consultation with the medical monitor.
Drug: Pegvaliase
40-60mg/day
Also known as: rAvPAL-PEG
Number of Participants With Treatment-emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0
A treatment-emergent AE was defined as any adverse event (AE) newly appearing or worsened in severity following initiation of study drug until 4 weeks after last dose of pegvaliase
Time frame: Up to Day 741 (approximately Week 106)
Change in Blood Phe Concentration
Change in blood phenylalanine (Phe) concentration from Parent Study baseline (naïve/pretreatment).
Time frame: The Outcome Measure Data Table below uses the 'analysis visit' as defined by the mapping rule in the SAP. The last Phe measurement was mapped to 'analysis visit' week 121. The actual date of the last Phe measurement was day 836 (approximately Week 119).
This was a multicenter study, conducted in 17 study centers in the United States involving subjects from either Parent Study 165-302 (NCT02468570) or Parent Study PAL-003 (NCT00924703).
| Milestone | All Subjects |
|---|---|
| Started | 37 |
| Completed | 35 |
| Not completed | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Subject received <= 40 mg/day for > 32 weeks | 1 |
A treatment-emergent AE was defined as any adverse event (AE) newly appearing or worsened in severity following initiation of study drug until 4 weeks after last dose of pegvaliase
| Participants | All Subjects |
|---|---|
| TEAE | 36 |
| Related TEAE | 17 |
| Serious TEAE | 7 |
| Related Serious TEAE | 1 |
Change in blood phenylalanine (Phe) concentration from Parent Study baseline (naïve/pretreatment).
| µmol/L | All Subjects |
|---|---|
| Parent Study Baseline (naïve/pretreatment) | 1376.9 ± 289.77 |
| Change from Baseline to Screening/Day 1 | -761 ± 506.7 |
| Change from Baseline at week 9 | -970.6 ± 513.6 |
| Change from Baseline at Week 17 | -963.4 ± 454 |
| Change from Baseline at Week 25 | -830.6 ± 599.8 |
| Change from Baseline at Week 33 | -999.8 ± 528 |
| Change from Baseline at Week 41 | -984.1 ± 545.6 |
| Change from Baseline at Week 49 | -1001.7 ± 518.3 |
| Change from Baseline at Week 57 | -867 ± 569.2 |
| Change from Baseline at Week 65 | -913.2 ± 445 |
| Change from Baseline at Week 73 | -896 ± 582.8 |
| Change from Baseline at Week 81 | -847.8 ± 504 |
| Change from Baseline at Week 89 | -962.3 ± 482.6 |
| Change from Baseline at Week 97 | -865.6 ± 567.4 |
| Change from Baseline at Week 105 | -817.4 ± 584.9 |
| Change from Baseline at Week 113 | -1319 ± 123 |
| Change from Baseline at Week 121 | -1123 ± NA |
Collected over Up to Day 741 (approximately Week 106). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Subjects | 0/37 (0%) | 7/37 (18.9%) | 36/37 (97.3%) |
| Event | All Subjects |
|---|---|
| COVID-19Infections and infestations | 1/37 |
| Wound infection staphylococcalInfections and infestations | 1/37 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/37 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 1/37 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 1/37 |
| Systemic inflammatory response syndromeGeneral disorders | 1/37 |
| CholecystitisHepatobiliary disorders | 1/37 |
| Anaphylactic reactionImmune system disorders | 1/37 |
| Event | All Subjects |
|---|---|
| NasopharyngitisInfections and infestations | 13/37 |
| HeadacheNervous system disorders | 12/37 |
| InfluenzaInfections and infestations | 7/37 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 7/37 |
| Amino acid level decreasedInvestigations | 7/37 |
| NauseaGastrointestinal disorders | 6/37 |
| VomitingGastrointestinal disorders | 6/37 |
| Injection site bruisingGeneral disorders | 6/37 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/37 |
| PruritusSkin and subcutaneous tissue disorders | 6/37 |
| Age, Continuous(years) | All Subjects |
|---|---|
| Mean | 28.84 ± 9.02 |
| Age, Customized(Participants) | All Subjects |
|---|---|
| 16 to < 18 years | 2 |
| Between 18 and < 66 years | 35 |
| >/= 66 years | 0 |
| Sex: Female, Male(Participants) | All Subjects |
|---|---|
| Female | 15 |
| Male | 22 |
| Ethnicity (NIH/OMB)(Participants) | All Subjects |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 36 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Subjects |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 36 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Weight(kg) | All Subjects |
|---|---|
| Mean | 94.9 ± 29.75 |
| Body Mass Index (BMI)(kg/m^2) | All Subjects |
|---|---|
| Mean | 32 ± 8.41 |
| Baseline Blood Phe(umol/L) | All Subjects |
|---|---|
| Mean | 1376.9 ± 289.77 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2018 to primary completion in Jan 2021, 28 months.
Results were first posted in Feb 2022, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegvaliase